Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors.

IF 23.5 1区 医学 Q1 ONCOLOGY
Wenqun Zhong, Zhiyuan Qin, Ziyan Yu, Jingbo Yang, Dongdong Yan, Nils W Engel, Neil C Sheppard, Yi Fan, Ravi Radhakrishnan, Xiaowei Xu, Leyuan Ma, Serge Y Fuchs, Carl H June, Wei Guo
{"title":"Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors.","authors":"Wenqun Zhong, Zhiyuan Qin, Ziyan Yu, Jingbo Yang, Dongdong Yan, Nils W Engel, Neil C Sheppard, Yi Fan, Ravi Radhakrishnan, Xiaowei Xu, Leyuan Ma, Serge Y Fuchs, Carl H June, Wei Guo","doi":"10.1038/s43018-025-00949-8","DOIUrl":null,"url":null,"abstract":"<p><p>The efficacy of chimeric antigen receptor (CAR) T cells against solid tumors is limited. The molecular mechanisms underlying CAR T cell resistance are yet to be elucidated and new strategies need to be developed to improve treatment outcomes. Here we report that solid tumors respond to CAR T cells by upregulating the secretion of small extracellular vesicles carrying tumor antigens, which are horizontally transferred to CAR T cells, leading to antigen recognition and CAR T cell fratricide. Engineered CAR T cells armored with Serpin B9, a major granzyme B inhibitor, show decreased fratricide and increased vitality, tumor infiltration, and antitumor activity in female mice. Moreover, Serpin B9-armored CAR T cells show higher efficacy than parental CAR T cells in treating solid tumors when combined with the anti-programmed death 1 antibody. Our study demonstrates a mechanism that limits CAR T cell function and suggests an improved strategy in tumor treatment.</p>","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":" ","pages":""},"PeriodicalIF":23.5000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s43018-025-00949-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The efficacy of chimeric antigen receptor (CAR) T cells against solid tumors is limited. The molecular mechanisms underlying CAR T cell resistance are yet to be elucidated and new strategies need to be developed to improve treatment outcomes. Here we report that solid tumors respond to CAR T cells by upregulating the secretion of small extracellular vesicles carrying tumor antigens, which are horizontally transferred to CAR T cells, leading to antigen recognition and CAR T cell fratricide. Engineered CAR T cells armored with Serpin B9, a major granzyme B inhibitor, show decreased fratricide and increased vitality, tumor infiltration, and antitumor activity in female mice. Moreover, Serpin B9-armored CAR T cells show higher efficacy than parental CAR T cells in treating solid tumors when combined with the anti-programmed death 1 antibody. Our study demonstrates a mechanism that limits CAR T cell function and suggests an improved strategy in tumor treatment.

克服细胞外囊泡介导的自相残杀改善了CAR - T细胞对实体肿瘤的治疗。
嵌合抗原受体(CAR) T细胞治疗实体瘤的疗效有限。CAR - T细胞耐药的分子机制尚未阐明,需要开发新的策略来改善治疗效果。在这里,我们报道实体肿瘤通过上调携带肿瘤抗原的细胞外小泡的分泌来对CAR - T细胞做出反应,这些小泡水平转移到CAR - T细胞中,导致抗原识别和CAR - T细胞自相残杀。用Serpin B9(一种主要的颗粒酶B抑制剂)装甲的工程化CAR - T细胞在雌性小鼠中显示出降低杀兄弟性和增加活力、肿瘤浸润和抗肿瘤活性。此外,Serpin b9装甲CAR - T细胞与抗程序性死亡1抗体联合治疗实体肿瘤时,表现出比亲本CAR - T细胞更高的疗效。我们的研究证明了一种限制CAR - T细胞功能的机制,并提出了一种改进的肿瘤治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nature cancer
Nature cancer Medicine-Oncology
CiteScore
31.10
自引率
1.80%
发文量
129
期刊介绍: Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信